Work

Phase 1 clinical trial of AMG 340, a prostate-specific membrane antigen (PSMA)-targeted T-cell engager with a novel low-affinity CD3 binding domain designed to mitigate toxicity for the treatment of metastatic castration-resistant prostate cancer (mCRPC).

Year: 2024

Type: conference-abstract

Source: Journal of Clinical Oncology

DOI: 10.1200/jco.2024.42.16_suppl.e14587

Authors: Gerald Steven Falchook, Meredith McKean, William Kevin Kelly, Manish R. Patel, Manojkumar Bupathi, Bobby Chi-Hung Liaw, Benjamin Garmezy, Irene Vuu, Kristen Smith, Priya Gokani, Martijn Lolkema, Lawrence Fong

Institutions: HealthONE, Sarah Cannon, Thomas Jefferson University Hospital, Florida Cancer Specialists & Research Institute, Icahn School of Medicine at Mount Sinai, Amgen (United States), Amgen (United Kingdom), Amgen (Netherlands), University of California, San Francisco

Language: English

Topic: Prostate Cancer Treatment and Research

Subfield: Pulmonary and Respiratory Medicine

Field: Medicine

Domain: Health Sciences

SDG: Good health and well-being

Open Access status: closed

Funder: Amgen

OpenAlex ID: W4399324593

Cites:

Cited by: 17

Related to: 10